Dr. Michel Lévesque, MD, FRCS, FACS

Dr. Levesque photoMichel Lévesque, MD, FRCS, FACS is a member of the Cedars-Sinai Medical Center Institute for Spinal Disorders, a Center of Excellence; Associate Clinical Professor of Neurosurgery, UCLA School of Medicine; and member, Brain Research Institute, UCLA School of Medicine. He has authored over 75 articles in professional journals, contributed chapters to many leading neurosurgery treatises and presented over 150 scientific abstracts. He is Board Certified in Neurological Surgery by the American Board of Neurological Surgeons and the Canadian Royal College of Surgeons.

Dr. Levesque’s current research includes the use of neural stem cells for neural repair in Parkinson’s disease, spinal cord injuries and other neurodegenerative disorders. He performs technically advanced minimally invasive surgical procedures, complex spinal reconstruction and artificial disc replacement.

Dr. Lévesque received his medical degree at University of Montreal and completed his neurosurgical training at the Montreal Neurological Institute and McGill University. He completed post-graduate studies in Neurosciences on central nervous system regeneration and transplantation at McGill University, where he also completed a fellowship in functional neurosurgery. Dr. Lévesque has been active in academic neurosurgery and neurosciences research since 1986. He is also Chairman of the Foundation for Neural Repair, a not-for-profit foundation sponsoring translational research to accelerate human trials using neural stem cells. He is also a member of the steering committee of the Canada-California Strategic Innovation Partnership.

He is a recipient of multiple grants and awards, including the P.R.O Quality of Life award and the Kantrowitz family award. He is a member of several professional organizations, including the American Association of Neurological Surgeons, the American College of Surgeons, the American Society of Neural Transplantation, the American Medical Association, the California Medical Association, and the Los Angeles County Medical Association.

He is a sought-after speaker regarding his pioneering research activities in the area of clinical use of neural stem cells and neural cell regeneration, most notably presenting to the United States Senate Subcommittee on Technology, the American Association of Neurological Surgeons annual meeting, and many other international organizations.

Los Angeles Neurosurgical Institute

8670 Wilshire Blvd
Suite 201
Beverly Hills, CA 90211

Phone: 310-659-6633

Disclaimer
The inclusion of links on this Website are to Websites that are maintained by third parties over whom Parkinson’s Resource Organization has no control. Such links do not imply endorsement of the material contained therein. Parkinsons Resource Organization makes no claims, representations, or warranties as to the accuracy, completeness, or appropriateness of these Web Sites or the information these websites contain.

About Editor

Comments

  1. mahboubeh says:

    Hi,

    My husband has primitive PD disease. We have 3 little children and need your help.

    Please tell me about your research and its conclusion. How can we benefit from it ?

    I truly appreciate your time and consideration.

    • 1) Thank you for your inquiry Mahboubeh Kamalzadeh. We are sorry to hear of your husband’s diagnosis. In a private message, please respond to the following questions. How long has he been diagnosed? Is he under the care of a movement disorder specialist? How would you measure the speed within which he is progressing in his disease process (using the 5 Stages as an example, which stage might he be in?) How old is he? Where do you live? Is there anyone else in his family with primitive PD?

      2) Parkinson’s resource Organization does not do research, we have been reporting on research that is being done at a biotech in San Diego, CA that A) for the first time in the history of mankind has been able to breach the blood-brain-barrier with their molecules and B) through the use of Smart® molecules, in mouse models, they have been able to target and destroy plaques that cause Parkinson’s symptoms, thereby theorizing the reversal of the disease process. This research is at least two years away from human clinical trials and that is based on their ability to generate enough investor dollars to reach this goal in that amount of time.

      We are happy to start this dialogue with you with your answers to questions asked in the paragraph 1 above. Other than the information outlined in paragraph 2 , which we are also happy to discuss, we know of no other technology that is able to breach the BBB and/or may be able to reverse the disease process.

      Please let us know if we can be of further assistance.

Speak Your Mind

*